BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms 10x...

June 19, 2026 | News

Single Use Support Launches Next-Generation RoSS.BLST Platform for Scalable Freeze-Thaw Bioprocessing

Single Use Support introduces the advanced RoSS.BLST, a blast freezing and thawing platform designed to deliver maximum process consistency and product qua...

June 18, 2026 | News

Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast in Lower-Risk Myelodysplastic Syndromes

Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 Ha...

June 17, 2026 | News

Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer

Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...

June 17, 2026 | News

Dimerix Signs Up to AU$481 Million Licensing Deal with Everest Medicines to Advance Phase 3 Kidney Disease Therapy Across Asia

Dimerix Limited (ASX: DXB), a biopharmaceutical company developing innovative therapies for rare inflammatory diseases, has entered into an exclusive licen...

June 17, 2026 | News

Harbour BioMed's Antibody Innovation Prevails in Major Patent Clash with Amgen

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's g...

June 16, 2026 | News

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

Rejuvenate Bio and Merck Animal Health Join Forces on Novel Animal Health Gene Therapy Programme

-- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate...

June 15, 2026 | News

Akeso Expands Immunology Franchise with Approval of Gumokimab for Psoriasis

Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...

June 15, 2026 | News

Simcere and Stanford Medicine Partner to Advance First-in-Class Therapy for Idiopathic Pulmonary Fibrosis

Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory stu...

June 15, 2026 | News

PromptBio Launches Agentic AI Platform to Accelerate Scientific Discovery

The PromptBio Platform combines conversational AI with multi-agent orchestration to accelerate discovery from hypotheses to insights PromptBio, a Californ...

June 11, 2026 | News

China Approves First-in-Human Trial of Antengene’s ATG-201 for Autoimmune Diseases

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

June 12, 2026 | News

China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...

June 10, 2026 | News

Stay Connected